Cargando…
Between evidence and commerce – the case of sufentanil sublingual tablet systems
Autores principales: | Bantel, C., Laycock, H. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814728/ https://www.ncbi.nlm.nih.gov/pubmed/29219168 http://dx.doi.org/10.1111/anae.14037 |
Ejemplares similares
-
An Open-Label Study of Sufentanil Sublingual Tablet 30 Mcg in Patients with Postoperative Pain
por: Hutchins, Jacob L, et al.
Publicado: (2018) -
Sufentanil Sublingual Tablet Reduces Postoperative Opioid Use Following Outpatient Plastic Surgery
por: Seify, Hisham
Publicado: (2022) -
Sufentanil sublingual tablet system (Zalviso(®)) as an effective analgesic option after thoracic surgery: An observational study
por: Fabio, Costa, et al.
Publicado: (2019) -
A Review of Sublingual Sufentanil Tablet (SST) and its Utility as an Analgesic Agent for Pain Procedures
por: Koushik, Sarang S., et al.
Publicado: (2022) -
Sufentanil sublingual tablet system for enhanced recovery after total knee arthroplasty: a prospective observational case study
por: Rineau, Emmanuel, et al.
Publicado: (2022)